Darolutamide

SCHEMBL29519795

C[C@@H](Cn1ccc(-c2ccc(C#N)c(Cl)c2)n1)NC(=O)c1cc([C@@H](C)O)[nH]n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Known targets — ChEMBL curated mechanism

The experimentally established mechanism targets of Darolutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 1)

	gene	UniProt	supporting neighbours	confidence
▸	AR known ✓	P10275	20/20	1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Darolutamide SCHEMBL17962599	1.00	AR (1.00)	AR
Darolutamide SCHEMBL13733117	1.00	AR (1.00)	AR
Darolutamide SCHEMBL29390245	1.00	AR (1.00)	AR
Darolutamide SCHEMBL16330936	1.00	AR (1.00)	AR
Darolutamide SCHEMBL17962596	1.00	AR (1.00)	AR
Darolutamide SCHEMBL17962572	1.00	AR (1.00)	AR
Darolutamide SCHEMBL17962573	1.00	AR (1.00)	AR
SCHEMBL21250261	0.94	AR (0.89)	AR
SCHEMBL17976533	0.93	AR (0.86)	AR
SCHEMBL20341041	0.92	AR (0.85)	AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
WO-2022063437-A1	COMPOSITIONS FOR THE TREATMENT OF SALIVARY GLAND CARCINOMA	JANSSEN PHARMACEUTICA NV (BE)	2022-03-31	—	—	WO	claimed
WO-2022063437-A1	COMPOSITIONS FOR THE TREATMENT OF SALIVARY GLAND CARCINOMA	JANSSEN PHARMACEUTICA NV (BE)	2022-03-31	—	—	WO	disclosed